STEVE ASELAGE - 31 May 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Director
Signature
/s/ Alane P. Barnes, by power of attorney
Issuer symbol
BCRX
Transactions as of
31 May 2022
Net transactions value
+$5,297
Form type
4
Filing time
02 Jun 2022, 16:43:06 UTC
Previous filing
12 May 2022
Next filing
09 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Award $5,297 +569 +1.7% $9.31 33,728 31 May 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250, prorated to $10,597.83 based on the increase in the annual retainer fee effective April 18, 2022.